Ipragliflozin丨CAS 761423-87-4

Ipragliflozin丨CAS 761423-87-4 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus (T2DM). It belongs to a class of oral antidiabetic drugs that lower blood glucose levels by inhibiting glucose reabsorption in the kidneys, promoting urinary glucose excretion. 

1. Treatment of Type 2 Diabetes Mellitus (T2DM)

Ipragliflozin丨CAS 761423-87-4 is used as:

Monotherapy in patients inadequately controlled by diet and exercise alone

Combination therapy with other antidiabetic agents, such as:

Metformin

DPP-4 inhibitors (e.g., sitagliptin)

Sulfonylureas

Insulin

It has been shown to significantly reduce HbA1c, fasting plasma glucose, and postprandial glucose levels.

2. Weight Management in T2DM

By promoting caloric loss through glucosuria, ipragliflozin contributes to modest weight reduction, an important benefit for overweight or obese individuals with diabetes.

3. Cardiovascular and Renal Benefits

While ipragliflozin's cardiovascular and renal outcomes have not been as extensively studied as other SGLT2 inhibitors (e.g., empagliflozin or dapagliflozin), the class effect includes:

Reduction in systolic blood pressure

Improved cardiovascular risk profile

Potential renal protection by reducing intraglomerular pressure and proteinuria

Ongoing studies are evaluating ipragliflozin's long-term impact on heart failure and chronic kidney disease (CKD).

4. Adjunctive Use in Metabolic Syndrome

In clinical practice, ipragliflozin is also considered in patients with features of metabolic syndrome, including hypertension, dyslipidemia, and central obesity, due to its glucose-lowering, weight-reducing, and BP-lowering effects.

1. Glucose Reduction Without Hypoglycemia

Unlike insulin or sulfonylureas, Ipragliflozin丨CAS 761423-87-4 works independently of insulin secretion, greatly lowering the risk of hypoglycemia, especially when used as monotherapy or with agents that don't cause hypoglycemia.

2. Weight Loss

Ipragliflozin leads to an average weight loss of 2–3 kg over 12–24 weeks, providing an added benefit in managing obesity-related complications in T2DM patients.

3. Blood Pressure Reduction

Reduces systolic blood pressure by approximately 3–5 mmHg, attributed to osmotic diuresis and natriuresis.

This effect helps manage hypertension, a common comorbidity in T2DM.

4. Improved Beta-cell Function and Insulin Sensitivity

Studies have shown that ipragliflozin may improve beta-cell function and reduce insulin resistance over time, helping to slow disease progression.

5. Convenient Dosing

Administered once daily orally

Suitable for long-term use

No need for dose titration in most patients

Ipragliflozin (CAS 761423-87-4) is an oral SGLT2 inhibitor that offers effective blood glucose control in patients with type 2 diabetes. Its primary applications include:

Lowering blood glucose

Promoting weight loss

Reducing blood pressure

Improving overall metabolic health

Key benefits include a low risk of hypoglycemia, once-daily dosing, and improvements in insulin sensitivity. While generally well-tolerated, it requires caution in patients at risk of genital infections, volume depletion, or renal impairment.

As part of the broader SGLT2 inhibitor class, ipragliflozin represents a modern, multi-benefit therapeutic option for managing T2DM and associated metabolic complications.